SCYNEXIS INC
SCYXNASDAQTrading Snapshot
- Day Range
- $3.85 – $4.01
- 52-Week Range
- $3.53 – $9.12
- Volume (shares)
- 18,010.52
- Avg Volume (shares)
- —
- Shares Outstanding
- 9.9M
- Next Earnings
- 2026-11-11
Fundamentals Snapshot
- Annual Revenue
- $21M
- Last Q Revenue
- $235,000
- P/E Ratio
- —
- P/S Ratio
- 2.0x
- EPS (TTM)
- $-2.16
- Dividend Yield
- —
- Dilution (1yr)
- +14.7%
SCYNEXIS INC
SCYX
StockOtter · stockotter.spaceAbout SCYNEXIS INC
SCYNEXIS, Inc. is a biotechnology company, which engages in the development of novel oral and intravenous triterpenoid antifungal for the treatment of several fungal infections, including vulvovaginal candidiasis, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections. The company was founded by Scot Kevin Huber, Terry Eugene Marquardt, Pierre Bernard Jacques Monnet, Russell J. Outcalt, and Yves Joseph Ribeill on November 4, 1999 and is headquartered in Jersey City, NJ.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Insufficient data for all five components.
Analyst Ratings
ⓘLatest News & Updates
SCYNEXIS to Participate in the 3rd Annual Guggenheim Healthcare Innovation Conference
JERSEY CITY, N.J., Oct. 29, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a clinical-stage biotechnology company dedicated to advancing innovative solutions for severe rare diseases, today announced that the SC
SCYNEXIS Completes Phase 1 Study of Intravenous SCY-247, a Novel, Triterpenoid Antifungal in Development for Treatment and Prevention of Invasive Fungal Diseases
JERSEY CITY, N.J., Oct. 22, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX) (“SCYNEXIS”, or the “Company”), a clinical-stage biotechnology company dedicated to advancing innovative solutions for severe rare diseas
SCYNEXIS to Feature SCY-247 in a Pipeline Presentation at IDWeek
JERSEY CITY, N.J., Oct. 21, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX) (“SCYNEXIS” or the “Company”), a clinical-stage biotechnology company dedicated to advancing innovative solutions for severe rare disease
SCYNEXIS (NASDAQ:SCYX) Stock Price Crosses Above Fifty Day Moving Average – Time to Sell?
SCYNEXIS, Inc. (NASDAQ: SCYX - Get Free Report) shares passed above its 50 day moving average during trading on Tuesday. The stock has a 50 day moving average of $4.93 and traded as high as $5.29. SCYNEXIS shares last tr
SCYNEXIS Announces Phase 1 Study Results for SCY-770, a Novel, Highly Selective, Oral Direct AMPK Activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
• SCY-770 was well tolerated with a favorable safety profile in healthy adult participants at higher doses than previously evaluated
Head-To-Head Survey: Amarin (NASDAQ:AMRN) and SCYNEXIS (NASDAQ:SCYX)
Amarin (NASDAQ: AMRN - Get Free Report) and SCYNEXIS (NASDAQ: SCYX - Get Free Report) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength